Compare PKE & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKE | DBVT |
|---|---|---|
| Founded | 1954 | 2002 |
| Country | United States | France |
| Employees | 125 | 90 |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 796.7M | 948.8M |
| IPO Year | 1994 | 2014 |
| Metric | PKE | DBVT |
|---|---|---|
| Price | $37.51 | $15.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.04 |
| AVG Volume (30 Days) | ★ 412.0K | 300.6K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | ★ 93.10 | 10.26 |
| EPS | ★ 0.56 | N/A |
| Revenue | N/A | ★ $5,636,000.00 |
| Revenue This Year | N/A | $35.04 |
| Revenue Next Year | N/A | $2,360.78 |
| P/E Ratio | $68.27 | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $15.23 | $8.51 |
| 52 Week High | $39.55 | $26.19 |
| Indicator | PKE | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 61.05 | 40.74 |
| Support Level | $31.16 | $12.63 |
| Resistance Level | $38.20 | $17.78 |
| Average True Range (ATR) | 2.01 | 1.09 |
| MACD | 0.57 | 0.07 |
| Stochastic Oscillator | 73.09 | 19.33 |
Park Aerospace Corp is an aerospace company that develops and manufactures composite materials used to produce composite structures for the aerospace market. Its products include film adhesives, lightning strike protection materials, specialty ablative materials for rocket motors and nozzles, and materials for radome applications. The Company offers composite materials designed for hand lay-up and automated fiber placement (AFP) manufacturing applications, which are used in jet engines, large and regional transport aircraft, military aircraft, unmanned aerial vehicles (UAVs), business jets, general aviation aircraft, and rotary wing aircraft. It operates in North America, Asia, and Europe, with North America generating maximum revenue.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.